{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:35:25Z","timestamp":1773282925081,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1053\/j.seminoncol.2004.08.005","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:58:14Z","timestamp":1131008294000},"page":"147-160","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S13","title":["Role of liposomal anthracyclines in the treatment of multiple myeloma"],"prefix":"10.1053","volume":"31","author":[{"given":"Mohamad A.","family":"Hussein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2004.08.005_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V31.1.1.1","article-title":"Melphalan therapy for plasma cell myeloma","volume":"31","author":"Alexanian","year":"1968","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib2","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.208.9.1680","article-title":"Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib3","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C","article-title":"High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma","volume":"53","author":"Lenhard","year":"1984","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib4","first-page":"851","article-title":"Plasma cell myeloma","volume":"107","author":"Bergsagel","year":"1972","journal-title":"Can Med Assoc J"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib5","first-page":"789","article-title":"Nitrosoureas in multiple myeloma","volume":"60","author":"Salmon","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.2830360303","article-title":"High-dose dexamethasone for refractory or relapsing multiple myeloma","volume":"36","author":"Friedenberg","year":"1991","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib7","first-page":"179","article-title":"Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma","volume":"51","author":"Salmon","year":"1967","journal-title":"Cancer Chemother Rep"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib8","first-page":"345","article-title":"Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma","volume":"59","author":"Alberts","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.1985.3.5.654","article-title":"Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma","volume":"3","author":"Costanzi","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood.V67.2.275.275","article-title":"Treatment of multiple myeloma with recombinant alpha-interferon","volume":"67","author":"Quesada","year":"1986","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1200\/JCO.1992.10.2.334","article-title":"Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma","volume":"10","author":"Gregory","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib12","series-title":"Cancer","first-page":"2344","article-title":"Plasma cell neoplasms","author":"Salmon","year":"1997"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJM199402173300709","article-title":"The treatment of multiple myeloma","volume":"330","author":"Alexanian","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib14","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/1097-0142(197208)30:2<382::AID-CNCR2820300213>3.0.CO;2-C","article-title":"Combination chemotherapy for multiple myeloma","volume":"30","author":"Alexanian","year":"1972","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib16","first-page":"145","article-title":"Proposed guidelines for protocol studies, II","volume":"4","year":"1973","journal-title":"Cancer Chemother Rep 3"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib17","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood.V91.7.2501","article-title":"Plasmablastic morphology\u2013An independent prognostic factor with clinical and laboratory correlates","volume":"91","author":"Greipp","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib18","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.1989.tb06269.x","article-title":"VAD chemotherapy for refractory multiple myeloma","volume":"71","author":"Lokhorst","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02076700","article-title":"Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen","volume":"61","author":"Stenzinger","year":"1990","journal-title":"Blut"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/bjc.1995.65","article-title":"VAD chemotherapy as remission induction for multiple myeloma","volume":"71","author":"Anderson","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib22","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(89)91549-3","article-title":"Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma","volume":"2","author":"Samson","year":"1989","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00000421-199512000-00003","article-title":"Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study","volume":"18","author":"Gertz","year":"1995","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2141.1992.tb08901.x","article-title":"VAD or VMBCP in severe multiple myeloma. The Groupe d\u2019Etudes et de Recherche sur le Myelome (GERM)","volume":"80","author":"Monconduit","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1046\/j.1365-2141.1998.00997.x","article-title":"VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85)","volume":"103","author":"Mineur","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/10428199509056859","article-title":"A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma","volume":"17","author":"Phillips","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2141.1992.tb06466.x","article-title":"Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: An NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group","volume":"82","author":"Browman","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.1999.01279.x","article-title":"Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma","volume":"105","author":"Segeren","year":"1999","journal-title":"Br J Haematol"},{"issue":"suppl 13","key":"10.1053\/j.seminoncol.2004.08.005_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2004.08.001","article-title":"Advantages of liposomal delivery systems for anthracyclines","volume":"31","author":"Allen","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib32","first-page":"28a","article-title":"Doxil, vincristine and dexamethasone","volume":"18","author":"Gautier","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1034\/j.1600-0609.2000.90145.x","article-title":"Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients","volume":"65","author":"Tsiara","year":"2000","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.08.005_bib34","first-page":"311b","article-title":"Doxil, vincristine, and Decadron","volume":"94","author":"Hussein","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib35","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/cncr.10946","article-title":"A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients","volume":"95","author":"Hussein","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib36","first-page":"380b","article-title":"Liposomal doxorubicin in the treatment of multiple myeloma","volume":"102","author":"Jajeh","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib37","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/1097-0142(197510)36:4<1192::AID-CNCR2820360403>3.0.CO;2-I","article-title":"Prognostic factors in multiple myeloma","volume":"36","author":"Alexanian","year":"1975","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib38","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.1995.13.9.2354","article-title":"Randomized trial of interferon maintenance in multiple myeloma","volume":"13","author":"Browman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib39","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/annonc\/mdg287","article-title":"Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma","volume":"14","author":"Dimopoulos","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib40","first-page":"453a","article-title":"DVd versus VAd in the treatment of patients with newly diagnosed multiple myeloma (n-MM)","volume":"102","author":"Hussein","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib41","first-page":"567","article-title":"Cost effectiveness of DVd vs VAd in newly diagnosed multiple myeloma","volume":"23","author":"Hussein","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib42","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib43","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib44","first-page":"409","article-title":"Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation","volume":"86","author":"Tosi","year":"2001","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2003.87","article-title":"Dermatologic side effects of thalidomide in patients with multiple myeloma","volume":"48","author":"Hall","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib47","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1093\/annonc\/mdf258","article-title":"The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma","volume":"13","author":"Grover","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib48","first-page":"237a","article-title":"Pegylated doxorubicin, vincristine, reduced frequency dexamethasone and thalidomide (DVd-T) in newly diagnosed and relapsed\/refractory multiple myeloma patients","volume":"102","author":"Agrawal","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdh026","article-title":"Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD Doxil)","volume":"15","author":"Zervas","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib50","first-page":"584","article-title":"Aspirin (ASA) prophylaxis during treatment (TTT) of multiple myeloma (MM) using liposomal doxorubicin, vincristine, decreased-frequency dexamethasone & thalidomide (DVd-T) decreases post-treatment thrombosis (DVT)","volume":"22","author":"Tso","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib51","first-page":"447a","article-title":"Intermediate analysis of a prospective randomised comparison of standard VAD protocol (vincristine, doxorubicin and dexamethasone) and pegylated liposomal doxorubicin (Doxil\/CAELYX) plus dexamethasone as a first-line treatment in multiple myeloma (MM)","volume":"102","author":"Rossi","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib52","first-page":"449a","article-title":"Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies","volume":"102","author":"Orlowski","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib53","first-page":"3111","article-title":"Prognostic value of bone marrow angiogenesis in multiple myeloma","volume":"6","author":"Rajkumar","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib54","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s002770000236","article-title":"Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma","volume":"79","author":"Sezer","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib55","first-page":"603","article-title":"The effects of different chemotherapeutic regimens on bone marrow microvessel density in patients with multiple myeloma","volume":"22","author":"He","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.seminoncol.2004.08.002","article-title":"Pegylated liposomal doxorubicin","volume":"31","author":"Vail","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/(SICI)1099-1069(199806)16:2<47::AID-HON622>3.3.CO;2-V","article-title":"Liposomal daunorubicin","volume":"16","author":"Pratt","year":"1998","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib58","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.10561","article-title":"Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study","volume":"94","author":"Mohrbacher","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.005_bib59","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/00001813-200311000-00004","article-title":"Liposomal daunorubicin (DaunoXome) in multiple myeloma","volume":"14","author":"Eucker","year":"2003","journal-title":"Anticancer Drugs"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404003823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404003823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T13:02:45Z","timestamp":1586523765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775404003823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":59,"alternative-id":["S0093775404003823"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2004.08.005","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}